1826-P: Comparison of OGTT-Model Measures with the Hyperglycemic Clamp in Youth and Adults with IGT or Early Type 2 Diabetes (DM)

Published on Jun 1, 2019in Diabetes7.199
· DOI :10.2337/db19-1826-P
Kristina M. Utzschneider35
Estimated H-index: 35
Andrea Mari56
Estimated H-index: 56
+ 9 AuthorsSteven E. Kahn98
Estimated H-index: 98
The Restoring Insulin Secretion (RISE) Study found that compared to adults (A), youth (Y) with early DM (33 Y, 104 A) or IGT (53 Y, 250 A) have higher insulin and C-peptide responses, even after adjusting for differences in insulin sensitivity. To better understand these differences, we compared mathematical modeling data from OGTTs to those from a hyperglycemic clamp within the RISE Study. Modeled measures were the dose-response relationship between glucose and insulin secretion (glucose sensitivity [GS], rate sensitivity [RS]) and the oral glucose insulin sensitivity index (OGIS). Clamp measures were insulin sensitivity (steady state glucose infusion rate/insulin [M/I]), acute (0-10 minutes) C-peptide (ACPRg) and insulin (AIRg) responses to glucose, steady-state C-peptide (SSCP) at plasma glucose of 11.1 mmol/L, and arginine-stimulated maximum C-peptide (ACPRmax) response at glucose >25 mmol/L. Linear regression models were fit to assess relationships between OGTT model and clamp measures by age group. GS (r 2 = 0.29, p 2 = 0.22, p 2 = 0.55, p 2 = 0.52, p 2 = 0.46, p 2 = 0.33, p 2 = 0.55, p 2 = 0.34, p Disclosure K. Utzschneider: Consultant; Self; Novo Nordisk Inc. A. Mari: Consultant; Self; Eli Lilly and Company. Research Support; Self; Boehringer Ingelheim International GmbH. M. Tripputi: None. K.J. Mather: Advisory Panel; Self; Roche Diabetes Care. Research Support; Self; Abbott, Merck & Co., Inc., Novo Nordisk A/S, Sanofi. K.J. Nadeau: None. S. Edelstein: None. T.S. Hannon: Advisory Panel; Self; Eli Lilly and Company. S.A. Arslanian: None. M. Cree-Green: None. T.A. Buchanan: Research Support; Self; Allergan, Apollo EndoSurgery. S. Caprio: None. S.E. Kahn: Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk A/S. Consultant; Self; Neurimmune. Other Relationship; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk A/S. R. Consortium: None. Funding American Diabetes Association (1-14-RISE-01 to S.E.K.); National Institute of Diabetes and Digestive and Kidney Diseases
  • References (0)
  • Citations (0)
📖 Papers frequently viewed together
78% of Scinapse members use related papers. After signing in, all features are FREE.
Cited By0